Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; ethylcellulose; titanium dioxide; povidone; macrogol 6000; hypromellose; purified talc; magnesium stearate; iron oxide red - for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; povidone; ethylcellulose; crospovidone; purified talc; iron oxide red; titanium dioxide; hypromellose; lactose monohydrate - for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; ethylcellulose; titanium dioxide; povidone; macrogol 6000; hypromellose; purified talc; magnesium stearate; iron oxide red - for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; povidone; ethylcellulose; crospovidone; purified talc; iron oxide red; titanium dioxide; hypromellose; lactose monohydrate - for the treatment of hypertension.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - phentolamine mesilate 10 mg/ml - solution for injection - 10 mg/ml - active: phentolamine mesilate 10 mg/ml excipient: carbon dioxide glucose sodium metabisulfite water for injection - regitine is indicated for: · therapeutic: management of hypertensive episodes that may occur in patients with phaeochromocytoma, during preoperative preparation and surgical manipulation. · diagnostic: diagnosis of phaeochromocytoma by regitine® blocking test if other more specific tests are not available. · preventive: prevention of dermal necrosis and sloughing after extravasation of noradrenaline

United States - English - NLM (National Library of Medicine)

qualitest products, inc. - diethylpropion hydrochloride (unii: 19v2pl39ng) (diethylpropion - unii:q94yyu22b8) - tablet, extended release - 75 mg - diethylpropion hydrochloride tablets are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regiment of weight reduction based on caloric restriction. the usefulness of agents of this class should be measured against possible risk factors inherent in their use such as those described (see clinical pharmacology). diethylpropion hydrochloride should not be used in patients with advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension, a history of drug abuse, or those in an agitated state (see precautions). diethylpropion hydrochloride should not be given during, or within fourteen days following, the administration of monoamine oxidase inhibitors; hypertensive crises may result. diethylpropion is a schedule iv controlled substance. diethylpropion has some chemical and pharmacologic similarities to the amphetamines and other related stimulant drugs that have been extensively abused.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate (unii: h527kap6l5) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - dextroamphetamine saccharate 1.25 mg - tablets of mixed salts of a single entity amphetamine product are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. attention deficit hyperactivity disorder (adhd) a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful.

Australia - English - Department of Health (Therapeutic Goods Administration)

phentolamine mesylate -

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - phentermine hydrochloride (unii: 0k2i505otv) (phentermine - unii:c045tql4wp) - phentermine 30 mg - phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2 , or ≥ 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). below is a chart of body mass index (bmi) based on various heights and weights. bmi is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters. body mass index (bmi), kg/m2 the limited usefulness of agents of this class, including phentermine hydrochloride tablets, [see clinical pharmacology (12.1, 12.2) ] should be measured against possible risk factors inherent in their use such as those described below. pregnancy category x phentermine is contraindicated during pregnancy because weight

United States - English - NLM (National Library of Medicine)

proficient rx lp - phentermine hydrochloride (unii: 0k2i505otv) (phentermine - unii:c045tql4wp) - phentermine hydrochloride 37.5 mg - phentermine hydrochloride tablets usp are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m2 , or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). below is a chart of body mass index (bmi) based on various heights and weights. bmi is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters. 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 the limited usefulnes